Clinical Trial Detail

NCT ID NCT02427893
Title Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Recruitment Withdrawn
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

melanoma

Therapies

Cobimetinib

Vemurafenib

Age Groups: adult

Additional content available in CKB BOOST